Posted by Michael Wonder on 06 Jun 2022
GBT’s inclacumab and GBT601 receive U.S. FDA orphan drug and rare paediatric disease designations for the treatment of sickle cell disease
6 June 2022 - Inclacumab is a novel P selectin inhibitor currently in Phase 3 clinical trials to reduce vaso-occlusive crises and readmissions due to vaso-occlusive crises in patients with sickle cell disease.
Global Blood Therapeutics today announced that the U.S. FDA has granted both orphan drug and rare paediatric disease designations for inclacumab and GBT021601 (GBT601) for the treatment of sickle cell disease.
